Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.54 |
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677959 | 1.00 | HRH3 (0.57) | HRH3HSD11B1OGACRBNPRKCQ | |
| SCHEMBL13059653 | 0.89 | PRKCQ (0.59) | HRH3HSD11B1OGACRBNPRKCQ | |
| SCHEMBL31753390 | 0.86 | HSD11B1 (0.49) | HRH3HSD11B1PRKCQTTRPDE10A | |
| SCHEMBL30790724 | 0.84 | HSD11B1 (0.55) | HSD11B1PRKCQTTRPDE10AIRAK4 | |
| Hydrochloric Acid SCHEMBL3281505 | 0.83 | HRH3 (0.58) | HRH3HSD11B1OGACRBNPRKCQ | |
| SCHEMBL14879861 | 0.82 | HRH3 (0.58) | HRH3HSD11B1OGACRBNPRKCQ | |
| SCHEMBL20548134 | 0.81 | HSD11B1 (0.59) | HRH3HSD11B1OGACRBNPRKCQ | |
| SCHEMBL24882086 | 0.81 | MEN1 (0.48) | — | |
| SCHEMBL3173613 | 0.80 | OGA (0.56) | HRH3HSD11B1OGACRBNPRKCQ | |
| SCHEMBL22849533 | 0.79 | IRAK4 (0.53) | HRH3HSD11B1OGACRBNIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | HRH3 474/4885HSD11B1 55/4885OGA 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.